Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis
<p>Abstract</p> <p>Background</p> <p>Metastatic pancreatic adenocarcinoma has a short median overall survival (OS) of 5–6 months. However, a subgroup of patients survives more than 1 year. We analyzed the survival outcomes of this subgroup and evaluated clinical and pat...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2009-03-01
|
| Series: | Journal of Hematology & Oncology |
| Online Access: | http://www.jhoonline.org/content/2/1/13 |
| _version_ | 1818834712298258432 |
|---|---|
| author | Muzikansky Alona Grenon Nina Ryan David P Lauwers Gregory Y Clark Jeffrey W Goulart Bernardo HL Zhu Andrew X |
| author_facet | Muzikansky Alona Grenon Nina Ryan David P Lauwers Gregory Y Clark Jeffrey W Goulart Bernardo HL Zhu Andrew X |
| author_sort | Muzikansky Alona |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Metastatic pancreatic adenocarcinoma has a short median overall survival (OS) of 5–6 months. However, a subgroup of patients survives more than 1 year. We analyzed the survival outcomes of this subgroup and evaluated clinical and pathological factors that might affect survival durations.</p> <p>Methods</p> <p>We identified 20 patients with metastatic or recurrent pancreatic adenocarcinoma who received single-agent gemcitabine and had an OS longer than 1 year. Baseline data available after the diagnosis of metastatic or recurrent disease was categorized as: 1) <it>clinical/demographic data </it>(age, gender, ECOG PS, number and location of metastatic sites); 2) <it>Laboratory data </it>(Hematocrit, hemoglobin, glucose, LDH, renal and liver function and CA19-9); 3) <it>Pathologic data </it>(margins, nodal status and grade); 4) <it>Outcomes data </it>(OS, Time to Treatment Failure (TTF), and 2 year-OS). The lowest CA19-9 levels during treatment with gemcitabine were also recorded. We performed a univariate analysis with OS as the outcome variable.</p> <p>Results</p> <p>Baseline logarithm of CA19-9 and total bilirubin had a significant impact on OS (HR = 1.32 and 1.31, respectively). Median OS and TTF on gemcitabine were 26.9 (95% CI = 18 to 32) and 11.5 (95% CI = 9.0 to 14.3) months, respectively. Two-year OS was 56.4%, with 7 patients alive at the time of analysis.</p> <p>Conclusion</p> <p>A subgroup of patients with metastatic pancreatic cancer has prolonged survival after treatment with gemcitabine. Only bilirubin and CA 19-9 levels were predictive of longer survival in this population. Further analysis of potential prognostic and predictive markers of response to treatment and survival are needed.</p> |
| first_indexed | 2024-12-19T02:39:10Z |
| format | Article |
| id | doaj.art-3978081b85d2415488239443ec66320e |
| institution | Directory Open Access Journal |
| issn | 1756-8722 |
| language | English |
| last_indexed | 2024-12-19T02:39:10Z |
| publishDate | 2009-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Hematology & Oncology |
| spelling | doaj.art-3978081b85d2415488239443ec66320e2022-12-21T20:39:11ZengBMCJournal of Hematology & Oncology1756-87222009-03-01211310.1186/1756-8722-2-13Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysisMuzikansky AlonaGrenon NinaRyan David PLauwers Gregory YClark Jeffrey WGoulart Bernardo HLZhu Andrew X<p>Abstract</p> <p>Background</p> <p>Metastatic pancreatic adenocarcinoma has a short median overall survival (OS) of 5–6 months. However, a subgroup of patients survives more than 1 year. We analyzed the survival outcomes of this subgroup and evaluated clinical and pathological factors that might affect survival durations.</p> <p>Methods</p> <p>We identified 20 patients with metastatic or recurrent pancreatic adenocarcinoma who received single-agent gemcitabine and had an OS longer than 1 year. Baseline data available after the diagnosis of metastatic or recurrent disease was categorized as: 1) <it>clinical/demographic data </it>(age, gender, ECOG PS, number and location of metastatic sites); 2) <it>Laboratory data </it>(Hematocrit, hemoglobin, glucose, LDH, renal and liver function and CA19-9); 3) <it>Pathologic data </it>(margins, nodal status and grade); 4) <it>Outcomes data </it>(OS, Time to Treatment Failure (TTF), and 2 year-OS). The lowest CA19-9 levels during treatment with gemcitabine were also recorded. We performed a univariate analysis with OS as the outcome variable.</p> <p>Results</p> <p>Baseline logarithm of CA19-9 and total bilirubin had a significant impact on OS (HR = 1.32 and 1.31, respectively). Median OS and TTF on gemcitabine were 26.9 (95% CI = 18 to 32) and 11.5 (95% CI = 9.0 to 14.3) months, respectively. Two-year OS was 56.4%, with 7 patients alive at the time of analysis.</p> <p>Conclusion</p> <p>A subgroup of patients with metastatic pancreatic cancer has prolonged survival after treatment with gemcitabine. Only bilirubin and CA 19-9 levels were predictive of longer survival in this population. Further analysis of potential prognostic and predictive markers of response to treatment and survival are needed.</p>http://www.jhoonline.org/content/2/1/13 |
| spellingShingle | Muzikansky Alona Grenon Nina Ryan David P Lauwers Gregory Y Clark Jeffrey W Goulart Bernardo HL Zhu Andrew X Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis Journal of Hematology & Oncology |
| title | Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis |
| title_full | Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis |
| title_fullStr | Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis |
| title_full_unstemmed | Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis |
| title_short | Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis |
| title_sort | long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine a retrospective analysis |
| url | http://www.jhoonline.org/content/2/1/13 |
| work_keys_str_mv | AT muzikanskyalona longtermsurvivorswithmetastaticpancreaticadenocarcinomatreatedwithgemcitabinearetrospectiveanalysis AT grenonnina longtermsurvivorswithmetastaticpancreaticadenocarcinomatreatedwithgemcitabinearetrospectiveanalysis AT ryandavidp longtermsurvivorswithmetastaticpancreaticadenocarcinomatreatedwithgemcitabinearetrospectiveanalysis AT lauwersgregoryy longtermsurvivorswithmetastaticpancreaticadenocarcinomatreatedwithgemcitabinearetrospectiveanalysis AT clarkjeffreyw longtermsurvivorswithmetastaticpancreaticadenocarcinomatreatedwithgemcitabinearetrospectiveanalysis AT goulartbernardohl longtermsurvivorswithmetastaticpancreaticadenocarcinomatreatedwithgemcitabinearetrospectiveanalysis AT zhuandrewx longtermsurvivorswithmetastaticpancreaticadenocarcinomatreatedwithgemcitabinearetrospectiveanalysis |